Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Endoxifen

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atossa Pharma Gets FDA Orphan Status For (Z)-Endoxifen
    Atossa Pharma Gets FDA Orphan Status For (Z)-Endoxifen

    16 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atossa-therapeutics-receives-fda-orphan-drug-designation-for-z-endoxifen-for-the-treatment-of-duchenne-muscular-dystrophy-302663760.html

    PR NEWSWIRE
    16 Jan 2026
    Share Share
    Atossa Pharma Receives 2025 Clinical Trials Arena Award
    Atossa Pharma Receives 2025 Clinical Trials Arena Award

    17 Dec 2025

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/atossa-therapeutics-wins-2025-clinical-trials-arena-research-and-development-excellence-award-in-precision-endocrine-therapy-category-302644202.html

    PR NEWSWIRE BIO
    17 Dec 2025
    Share Share
    Atossa Therapeutics Presents (Z)-Endoxifen Updates at 2025 SABCS
    Atossa Therapeutics Presents (Z)-Endoxifen Updates at 2025 SABCS

    15 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atossa-therapeutics-presents-four-clinical-trial-updates-highlighting-z-endoxifen-research-at-the-2025-san-antonio-breast-cancer-symposium-302641613.html

    PR NEWSWIRE
    15 Dec 2025
    Share Share
    Atossa Pharma Gets FDA Rare Pediatric Disease Status For DMD
    Atossa Pharma Gets FDA Rare Pediatric Disease Status For DMD

    11 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atossa-therapeutics-receives-fda-rare-pediatric-disease-designation-for-z-endoxifen-for-duchenne-muscular-dystrophy-302638744.html

    PR NEWSWIRE
    11 Dec 2025
    Share Share
    Atossa Therapeutics Secures U.S. Patent for Oral (Z)-Endoxifen
    Atossa Therapeutics Secures U.S. Patent for Oral (Z)-Endoxifen

    09 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-issuance-of-us-patent-covering-enteric-oral-z-endoxifen-formulations-and-methods-of-treating-patients-using-z-endoxifen-302635035.html

    PR NEWSWIRE
    09 Dec 2025
    Share Share
    Atossa Accelerates (Z)-Endoxifen for Breast Cancer
    Atossa Accelerates (Z)-Endoxifen for Breast Cancer

    04 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atossa-therapeutics-details-accelerated-fda-strategy-to-advance-z-endoxifen-across-breast-cancer-continuum-302632695.html

    PR NEWSWIRE
    04 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.